This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Study Shows NxStage Daily Home Hemodialysis Patients More Likely To Receive Kidney Transplant

LAWRENCE, Mass., May 11, 2012 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq:NXTM), a leading manufacturer of innovative dialysis products, today commented on findings of the Chronic Disease Research Group (CDRG) study showing that patients receiving daily, or more frequent, home hemodialysis with the NxStage System Oneā„¢ are more likely to receive a kidney transplant when compared with conventional thrice-weekly dialysis, particularly in patients not on the transplant waitlist at initiation of daily home hemodialysis. The study, "Transplant Rates in Frequent Hemodialysis and Matched Thrice-Weekly Hemodialysis Patients," was presented on Thursday, May 10th at the National Kidney Foundation Spring Clinical Meeting in Washington, D.C.

(Logo: )

The CDRG retrospective cohort study compared cumulative incidence of transplant in 1,873 daily home hemodialysis patients using the NxStage System One from 2005 to 2007 and a matched cohort of 9,365 thrice-weekly, in-center hemodialysis patients from the United States Renal Data System (USRDS) database. The study was designed using a unique, rigorous matching process with 17 covariates that could impact transplantation incidence, including demographics, comorbidity and socioeconomic status. Specifically, findings showed:
  • Relative transplant incidence with daily home hemodialysis was 1.14 (P = 0.03) as compared with thrice-weekly in-center hemodialysis, but relative incidence varied by waitlist status at the start of follow-up; and
  • In patients on the transplant waitlist at the start of follow-up, relative transplant incidence was 0.93 (P = 0.27) as compared with thrice-weekly in-center hemodialysis; in patients not listed, relative incidence was 1.91 (P < 0.01);

"Kidney transplantation is widely regarded as the 'gold standard' treatment for End Stage Renal Disease and is associated with the highest quality of life and survival outcomes for patients," said Dr. Allan Collins, professor of medicine, University of Minnesota, and Director, Chronic Disease Research Group. "Daily home hemodialysis patients may be better prepared for a transplant based on earlier studies of frequent dialysis showing less hypertension, better phosphorus control, and reduced left ventricular hypertrophy."

"The CDRG study adds new and important findings to the large body of clinical data showing the significant benefits of more frequent home hemodialysis," said Jeffrey H. Burbank, Chief Executive Officer of NxStage. "This provides additional testament to the value our technology and therapy delivers to patients and the health care system.  Not only are transplants wonderful from an outcomes perspective, but also, they are the lowest long term cost of care option for Medicare."

CDRG is a nonprofit division of the Minneapolis Medical Research Foundation committed to investigating chronic illness to improve public health, including leveraging USRDS data to conduct studies. This study was funded by NxStage Medical.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs